Developing small molecules to target tau pathology in Alzheimer's disease
Targeting MSUT2 with small molecules to ameliorate pathological tau
['FUNDING_OTHER'] · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · NIH-10735826
This study is looking for new medicines that can help fight Alzheimer's disease by targeting a specific protein called MSUT2, which is linked to the harmful buildup of tau in the brain, and it’s for anyone interested in finding better treatments for this condition.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SEATTLE INST FOR BIOMEDICAL/CLINICAL RES (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10735826 on ClinicalTrials.gov |
What this research studies
This research focuses on developing small molecules that target MSUT2, a protein involved in tau pathology, which is a key factor in Alzheimer's disease and related dementias. The approach includes high-throughput screening of over 100,000 compounds to identify those that can inhibit MSUT2's interaction with poly(A) RNA, potentially slowing or reversing tau-related neurodegeneration. By understanding how MSUT2 modulates tau toxicity, the research aims to create effective therapeutics that directly address the underlying causes of Alzheimer's disease rather than just alleviating symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related tauopathies who are experiencing cognitive decline.
Not a fit: Patients with non-tau related forms of dementia or those without a diagnosis of Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that modify the progression of Alzheimer's disease by targeting tau pathology.
How similar studies have performed: While there has been limited success in targeting tau pathology directly, this approach is innovative and aims to fill a significant gap in current Alzheimer's treatment strategies.
Where this research is happening
SEATTLE, UNITED STATES
- SEATTLE INST FOR BIOMEDICAL/CLINICAL RES — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KRAEMER, BRIAN C. — SEATTLE INST FOR BIOMEDICAL/CLINICAL RES
- Study coordinator: KRAEMER, BRIAN C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease